AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04129918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: light and sound modification (earplugs and eye masks)
Description: In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
Study NCT01892137 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ingenol mebutate gel 0.05%
Description: Once daily for 2 consecutive days
Study NCT00153361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion Group
Study NCT00153361 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Discussion Group
Study NCT02767375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin(OXA), 5-fluorouracil (5-FU)
Description: for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks
Study NCT02767375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial catheter implantation
Description: for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
Study NCT03240913 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baseline and Follow-up Surveys
Description: (completed online)
Study NCT03240913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline and Follow-up Surveys
Description: (completed online)
Study NCT03240913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measure informed Decision Aid
Description: (PROM-DA)
Study NCT03240913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pamphlet
Description: (usual care)
Study NCT04140383 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract Surgery
Description: Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.
Study NCT01097239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonablate 500 (High Intensity Focused Ultrasound (HIFU))
Description: High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
Study NCT00928746 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ipratropium bromide
Study NCT01674712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination of Fenofibrate/simvastatin 145/20 mg
Description: Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
Study NCT01674712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
Study NCT01674712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 145 mg
Description: Fenofibrate, tablet, 145 mg, once daily, 12 weeks
Study NCT01674712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination of Fenofibrate/simvastatin 145/40 mg
Description: Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
Study NCT01674712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40 mg
Description: simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
Study NCT04460677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Support Plan
Description: The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
Study NCT04460677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Monitoring
Description: The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
Study NCT03302000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Visual Stimulation
Description: Early visual stimulation
Study NCT03302000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard care
Study NCT03302000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: standard care
Study NCT01810237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran.
Description: Dabigatran will be used instead of LMWH for anticoagulation bridging.
Study NCT02323633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Braingear Brainbuds Pulsed Current stimulation device
Description: Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
Study NCT02323633 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No transcranial Pulsed Current Stimulation (tPCS)
Study NCT01782079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. brevis
Study NCT01284062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anrukinzumab
Description: 200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Study NCT01284062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anrukinzumab
Description: 200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Study NCT01284062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anrukinzumab
Description: 200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
Study NCT01284062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Study NCT04624490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xe129
Description: During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
Study NCT02690779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
Study NCT02690779 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine Care Instructions
Description: patients will follow routine care and instructions
Study NCT06465888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: egg whites
Description: Participants will eat four egg whites daily for the 4-week study
Study NCT06465888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole eggs
Description: Participants will eat two eggs daily for the 4-week study
Study NCT06465888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 eggs
Description: Participants will eat two Christopher Farms omega-3 fortified eggs daily for the 4-week study.
Study NCT06465888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: egg yolk
Description: Participants will eat four egg yolks daily for the 4-week study
Study NCT04307082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Ibrexafungerp
Description: Radio-labeled Ibrexafungerp, single dose.
Study NCT04417101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb
Description: The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
Study NCT04113668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days
Study NCT04113668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diflunisal
Description: Specified Dose on Specified Days
Study NCT01207232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: A prompt to write down a planned date (or date and time) for getting a flu shot
Study NCT01207232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A basic reminder mailing prompted each subject to get their flu shot.
Study NCT00711256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sunscreen MATAS sunlotion SPF 8
Study NCT00711256 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB light
Description: duration 4 times 1 minute radiation on the trunk.
Study NCT02390817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Administration of Sugammadex
Study NCT02390817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine
Description: Administration of Neostigmine
Study NCT00849654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days.
Study NCT00056862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 90 mcg/week
Study NCT00056862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: 180 mcg/week
Study NCT00056862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800 mg/day
Study NCT00056862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800 mg/day
Study NCT03519958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma-tissue testing
Description: EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
Study NCT03749603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIBAY Meter
Description: fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
Study NCT00435474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound treatment
Description: wound treatment (silver product, alginate and foam dressing)
Study NCT00435474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound treatment
Description: wound treatment (honey product, alginate and foam dressing)
Study NCT00435474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho-social support
Description: psycho-social support (based on the structure in cognitive therapy)
Study NCT00435474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-social support
Description: psycho-social support (based on the structure in cognitive therapy)
Study NCT00435474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: relaxation therapy
Description: relaxation therapy
Study NCT00435474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation therapy
Description: relaxation therapy
Study NCT04562194 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retriever
Description: mechanical neurothrombectomy
Study NCT02900469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab: 120 mg subcutaneous injection
Study NCT02900469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery: approximately 2-4 weeks after dosing of denosumab
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 125 mcg once daily
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 62.5 mcg once daily
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 31.25 mcg once daily
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 15.6 mcg once daily
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 31.25 mcg twice daily
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 15.6 mcg twice daily
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 18 mcg once daily
Study NCT01372410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once or twice daily
Study NCT00146679 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Telephone counseling (TC)
Description: Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
Study NCT00146679 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Intervention by Group (SG)
Description: Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
Study NCT00146679 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care provided by providers
Study NCT02297360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Viviscal Extra-Strength Supplement
Description: The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
Study NCT02297360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
Study NCT02929797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8+NKG2D+ AKT Cell
Description: AKT: CD8+NKG2D+ AKT cell
Study NCT02929797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine
Study NCT02929797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine
Study NCT03876990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Description: Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
Study NCT03876990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Current strategy alone
Description: Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
Study NCT00859950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
Study NCT01243697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desogestrel
Description: Tablets of 75 µg, once daily during 112 days
Study NCT03141554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Betadine® PVP-I based mouth wash and gargle,
Description: 1% Betadine® PVP-I based mouth wash and gargle
Study NCT03141554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Description: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Study NCT03141554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline gargle
Description: Normal saline gargle
Study NCT01589354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Description: An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
Study NCT01589354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Ropivacaine injection
Description: The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
Study NCT01589354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided technique
Description: The block will be performed under U/S guidance
Study NCT01589354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20ml of 0.375% Ropivacaine
Study NCT01589354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
Study NCT01993446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRM02
Study NCT01993446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT02183285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmaton PHL 00747 soft gelatine capsules
Study NCT02183285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmaton PHL 00747 film-coated tablets
Study NCT02183285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo film-coated tablets (fct)
Study NCT02183285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo film-coated tablets (fct)
Study NCT02183285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo soft gelatine capsules
Study NCT02183285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft gelatine capsules
Study NCT02629289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HSP-130
Study NCT02629289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: US-approved Neulasta
Study NCT02629289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EU-approved Neulasta
Study NCT02729389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Social Status Condition
Description: Participants will be provided with a high degree of privilege in a game of Monopoly.
Study NCT02729389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Social Status Condition
Description: Participants will be provided with a low degree of privilege in a game of Monopoly.
Study NCT02623374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-help CBT intervention (SHCBT)
Description: See 'Arms' section
Study NCT03693456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conjunctival Allergen Challenge
Description: Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
Study NCT01303263 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Intervention
Description: 45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
Study NCT00472329 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors
Study NCT00472329 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: fludarabine
Study NCT00472329 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: TBI
Study NCT02129920 — intervention group
Intervention type: OTHER
Intervention: This is an observational study
Study NCT00780754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: 0.5mg
Study NCT00780754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsy
Description: prostate biopsy
Study NCT00780754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prostate biopsy
Description: prostate biopsy